

## **US FDA successfully inspects Peptisyntha's Peptide APIs manufacturing plant in Belgium**

Brussels, Belgium - Peptisyntha, one of the world's leading therapeutic peptides manufacturing companies, is pleased to announce the successful outcome of the recent inspection of its manufacturing facility in Brussels, Belgium by the United States Food and Drug Administration (FDA).

The FDA inspection, which lasted 4 days, was a general cGMP (current Good Manufacturing Practice) inspection relating to the commercial peptide APIs manufactured by Peptisyntha for the US market.

"The system-based inspection that covered all six major systems resulted in no Form 483 and no oral observations. This demonstrates our strict adherence to quality in all aspects of the programs for our customers", said Kristien Peetermans, Peptisyntha's Quality Affairs Manager.

"Following last summer's successful inspection of our site by the Belgian authorities on behalf of EMEA, we are very glad with this additional successful outcome from this FDA inspection", commented Johan Devenyns, Peptisyntha's Managing Director.

### About Peptisyntha

Peptisyntha, headquartered in Brussels, Belgium, is a company dedicated to the custom process development, scale-up and commercial production of peptides, servicing the pharmaceutical, biotech and related industries for more than 20 years. Peptisyntha operates 2 cGMP development and manufacturing sites: Peptisyntha SA (Belgium) specialized in solution phase peptide synthesis and Peptisyntha Inc. (USA) specialized in solid phase peptide synthesis.

For more information about Peptisyntha please visit the company's website at <http://www.peptisyntha.com>

Contact: Peptisyntha SA – rue de Ransbeek 310 – 1120 Brussels – Belgium , email: [info.peptisyntha@solvay.com](mailto:info.peptisyntha@solvay.com)